Is Wockhardt a good stock to invest in?

Wockhardt can be analyzed on the following key metrics - TTM P/E: - Sector P/E: 27.14 Dividend Yield: 0% D/E ratio: -

Home > Market > Market Stats > Wockhardt

Wockhardt Share Price

Sector: Biotechnology & Drugs

153.95 +3.05 (2.02%)

Price Range

Today’s Low 150.9

Today’s High 156.3

52 Week Low 145.35

52 Week High 315.5

Key Metrics

Market Cap (In Cr) 2174.29
Beta 1.98
Div. Yield (%) 0
P/B 0.56
TTM P/E -
Sector P/E 27.14
D/E -
Open Price 150.9
Prev Close 150.9

View All Metrics on Mint Genie

Wockhardt Analysis

Price Analysis

1 Week

-13.15%
3 Months

-32.36%
6 Month

-36.66%
YTD

-32.35%
1 Year

-46.51%

Risk Meter

30% Low risk
30% Moderate risk
30% Balanced Risk
30% High risk
30% Extreme risk

Wockhardt Financials

INCOME
BALANCE SHEET
Cashflow

DATE

Annual

Quarterly

Period
2022

Total Revenue
3230

Selling/ General/ Admin Expenses Total
1353

Depreciation/ Amortization
247

Other Operating Expenses Total
225

Total Operating Expense
3362

Operating Income
-132

Net Income Before Taxes
-411

Net Income
-244

Diluted Normalized EPS
-10.37

Period
2021

Total Revenue
2708.3

Selling/ General/ Admin Expenses Total
1251.53

Depreciation/ Amortization
246.02

Other Operating Expenses Total
248.68

Total Operating Expense
3157.37

Operating Income
-449.07

Net Income Before Taxes
-568.34

Net Income
686.06

Diluted Normalized EPS
-22.32

Period
2020

Total Revenue
2843.99

Selling/ General/ Admin Expenses Total
1152.7

Depreciation/ Amortization
224.14

Other Operating Expenses Total
265.41

Total Operating Expense
2970.37

Operating Income
-126.38

Net Income Before Taxes
-342.04

Net Income
-69.22

Diluted Normalized EPS
-13.64

Period
2019

Total Revenue
3565.84

Selling/ General/ Admin Expenses Total
1462.74

Depreciation/ Amortization
163.95

Other Operating Expenses Total
340.44

Total Operating Expense
3742.91

Operating Income
-177.07

Net Income Before Taxes
-446.55

Net Income
-194.53

Diluted Normalized EPS
-24.13

Period
2018

Total Revenue
3936.9

Selling/ General/ Admin Expenses Total
1705.17

Depreciation/ Amortization
149.53

Other Operating Expenses Total
360.54

Total Operating Expense
4500.05

Operating Income
-563.15

Net Income Before Taxes
-641.15

Net Income
-608.3

Diluted Normalized EPS
-29.64

Period
2017

Total Revenue
4014.61

Selling/ General/ Admin Expenses Total
1792.39

Depreciation/ Amortization
148.93

Other Operating Expenses Total
318.69

Total Operating Expense
4137.32

Operating Income
-122.71

Net Income Before Taxes
-247.15

Net Income
-195.72

Diluted Normalized EPS
-16.32

View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue

Returns Metrics (In Cr) ROA Vs ROE

Forecast

Balance Sheet Asset vs Liability

Forecast

Cash Flow Operating vs Investing

Wockhardt Peers

Price
Ratio

Name
Latest Price
Change
% Change
52W High
52W Low
Mkt. Cap

Advanced Enzyme Technologies
231.75
-7.15
-2.99
328.35
225
2590.98

Strides Pharma Science
289.2
-4.85
-1.65
392.2
263.45
2596.73

Wockhardt
153.95
3.05
2.02
315.5
145.35
2217.81

Dishman Carbogen Amcis
125
-4.75
-3.66
201.35
80.05
1959.79

Shilpa Medicare
228.8
0.4
0.18
503.05
222.4
1986.03

Wockhardt Shareholding

Category
Percentage
No. of shares

Public Shareholding
39.64%
57,104,077

Others
25%
36,008,458

Rekha Rakesh Jhunjhunwala
2.08%
3,000,005

Others
3.17%
4,577,467

Others
3.29%
4,742,847

Others
2.86%
4,118,784

HUF
1.26%
1,819,665

LLP
0.4%
581,498

Clearing Members
0.1%
147,554

Director or Director's Relatives
0.01%
11,000

Unclaimed or Suspense or Escrow Account
0.01%
10,200

Trusts
0%
1,950

Others
1.05%
1,516,183

Others
0.18%
266,412

Others
0.16%
226,844

Others
0.04%
55,405

Foreign Bank
0.01%
10,200

Foreign Institutional Investors
0%
1,200

Others
0%
5,549

Others
0%
1,475

Others
0%
751

Others
0%
630

Promoter & Promoter Group Shareholding
60.36%
86,956,076

Themisto Trustee Company Private Limited
49.41%
71,174,744

Callirhoe Trustee Company Private Limited
3.54%
5,096,751

Pasithee Trustee Company Private Limited
3.52%
5,070,000

Ananke Trustee Company Private Limited
3.08%
4,434,530

Habil F Khorakiwala
0.41%
597,286

Murtaza Habil Khorakiwala
0.2%
294,060

Huzaifa Habil Khorakiwala
0.19%
280,800

Nafisa Habil Khorakiwala
0%
5,565

Miqdad H Khorakiwala
0%
2,340

Shareholding Pattern

*Promoter pledging: 33.85%

Shareholding Trend

Shareholding(%) v/s Date

Corporate Actions

Board Meeting
AGM
Dividends
Bonus
Split
Rights

Meeting Date
Purpose

13-Feb-23
Quarterly Results

04-Nov-22
Quarterly Results

12-Aug-22
Quarterly Results

30-May-22
Audited Results

03-Mar-22
Rights issue

27-Jan-22
Quarterly Results

06-Jan-22
Rights issue of Equity Shares

08-Nov-21
Quarterly Results

22-Jul-21
Quarterly Results

27-May-21
Audited Results & Others

Meeting Date
Announced on
Purpose

02-Aug-21
08-Jul-21
AGM

Announced on
Record Date
Ex-Rights Date
Ratio
FV
Premium
Description

06-Jan-22
09-Mar-22
08-Mar-22
3:10
5
220
Rights issue of equity shares of Rs. 5/- each in the ratio of 3:10 @ premium of Rs. 220/-.

Company Profile

ABOUT Wockhardt

Industry Biotechnology & Drugs
ISIN INE049B01025
BSE Code 532300
NSE Code WOCKPHARMA

Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. The Company has approximately three research centers globally and a chain of six super-specialty hospitals across Maharashtra and Gujarat.

MANAGEMENT

Habil Fakhruddin Khorakiwala Executive Chairman of the Board
Pramod Gupta Chief Financial Officer
Debashis Dey Chief Compliance Officer, Company Secretary
Murtaza Habil Khorakiwala Managing Director, Executive Director
Huzaifa Habil Khorakiwala Executive Director

WOCKHARDT SUMMARY

Wockhardt is trading 2.02% upper at Rs 153.95 as compared to its last closing price. Wockhardt has been trading in the price range of 156.3 & 150.9. Wockhardt has given -32.35% in this year & -13.15% in the last 5 days.

The company posted a net profit of -96 Crores in its last quarter.

Listed peers of Wockhardt include Advanced Enzyme Technologies (-2.99%), Strides Pharma Science (-1.65%), Wockhardt (2.02%) etc.

Wockhardt has a 60.36% promoter holding & 39.64% public holding.

FAQs about Wockhardt

Wockhardt is trading at 153.95 as on 31 Mar, 2023 3:42:24 PM. This is 2.02% upper as compared to its previous closing price of 150.9

The market capitalization of Wockhardt is 2174.29 Cr as on 31 Mar, 2023 3:42:24 PM.

The 52 wk high for Wockhardt is 315.5 whereas the 52 wk low is 145.35

Wockhardt can be analyzed on the following key metrics -

TTM P/E: -
Sector P/E: 27.14
Dividend Yield: 0%
D/E ratio: -

Wockhardt reported a net profit of -244 Cr in 2022.

Wockhardt Share Price

Price Range